Iceland vs Palestine, State of: Tuberculosis cases
Iceland
12 cases
in 2024
Palestine, State of
16 cases
in 2024
Iceland rank
187th
Palestine, State of rank
185th
Tuberculosis cases over time
- Iceland
- Palestine, State of
How they compare
Palestine, State of currently reports 16 cases against 12 cases in Iceland, a difference of 4 cases.
That makes Palestine, State of's figure about 1.3 times Iceland's.
Across all 25 years both countries report, Palestine, State of has been ahead every year.
Iceland ranks 187th and Palestine, State of ranks 185th of 215 countries.
Palestine, State of has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Iceland | Palestine, State of | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 9.9 cases | 86.5 cases | 76.6 cases | Palestine, State of |
| 2010s | 10.6 cases | 52.2 cases | 41.6 cases | Palestine, State of |
| 2020s | 12.2 cases | 28.4 cases | 16.2 cases | Palestine, State of |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis cases, Iceland or Palestine, State of?
- Palestine, State of, at 16 cases against 12 cases in Iceland as of 2024.
- What is the difference in tuberculosis cases between Iceland and Palestine, State of?
- 4 cases, with Palestine, State of ahead.
- How many years of comparable data are there for Iceland and Palestine, State of?
- 25 years are reported by both, from 2000 to 2024.
- How do Iceland and Palestine, State of rank globally for tuberculosis cases?
- Iceland ranks 187th and Palestine, State of ranks 185th of 215 countries.
- Where does this data come from?
- WHO (2025) β with minor processing by Our World in Data, published as Tuberculosis cases. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The estimated number of new and relapse tuberculosis cases arising in a given year. All forms of the disease are included, including cases in people living with HIV.